| 초록 |
Objectives: This study aimed to evaluate the patterns of kidney involvement after corticosteroid use for control of extrarenal symptoms in patients with Henoch-schönlein purpura (HSP) and the difference between patients without corticosteroid use for symptom control. Methods: We conducted a retrospective cohort study of pediatric patients diagnosed with HSP who presented to the emergency department of single tertiary medical center between January 2019 and December 2025. Patients fulfilling the EULAR/PRINTO/PRES consensus classification criteria for HSP were included, and patients transferred to another hospital, lost to follow-up, or with insufficient clinical data were excluded. The primary outcomes were the presence of kidney involvement and the timing after HSP diagnosis, comparing patients who have received corticosteroid with those who did not. Results: A total of 211 patients were included. Of these, 92 patients received systemic corticosteroid treatment for extrarenal symptoms, while 119 did not. Kidney involvement occurred more frequently in the steroid-treated group than in the non–steroid-treated group (22.5% vs. 11.7%, p= 0.051). There was no significant difference in the time to onset of kidney involvement between the two groups (1.03 months vs. 0.72 months). Among patients who developed kidney involvement, microscopic hematuria with proteinuria pattern was more common in the steroid-treated group, with higher odds ratios observed especially in mild proteinuria (Protein creatinine ratio <1000 mg/g), although some comparisons did not reach statistical significance. There were no significant differences in the patterns of kidney involvement based on the cumulative steroid dose. Conclusion: Steroid treatment for extrarenal symptoms did not significantly alter the timing and severity of kidney involvement. However, some differences in the severity patterns and time range until presentation of kidney involvement were observed between two groups. |